A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations.

ABSTRACT: Balovaptan is a brain-penetrating vasopressin receptor 1a antagonist previously investigated for the core symptoms of autism spectrum disorder (ASD). A population pharmacokinetic (PK) model of balovaptan was developed, initially to assist clinical dosing for adult and pediatric ASD studies and subsequently for new clinical indications including malignant cerebral edema (MCE) and post-traumatic stress disorder. The final model incorporates one-compartment disposition and describes time- and dose-dependent non-linear PK through empirical drug binding and a gut extraction component with turnover. An age effect on clearance observed in children was modeled by an asymptotic function that predicts adult-equivalent exposures at 40% of the adult dose for children aged 2-4 years, 70% for 5-9 years,

SUBMITTER: Schaedeli Stark F 

PROVIDER: S-EPMC11136808 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature